Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
· ·
$0.62
▲ $0.00 (+0.8%)
Market data updated: 09/23 05:04 AM
Fundamentals updated: 09/23/2026
News analyzed: 09/23/2026
Market Cap
$20.73M
Day Range
$0.61 - $0.65
52-Week Range
$0.32 - $2.69
Beta
—
Next Earnings
09.11.2026
Support
$0.55
Resistance
$1.03
-75.9% (1Y)
Strengths: 5/21 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 2.62
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 11.5% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
49
Quality
No data available
Value
50
Momentum
32
Risk
40
Sentiment
74
Fundamental
46
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Jasper Therapeutics has primarily centered on its financial performance and strategic shifts. The company reported a narrower-than-expected loss in Q2 2026, though shares dipped afterward. Notably, Jasper completed a merger with Kira Pharmaceuticals in July 2026, aiming to bolster its immune drug pipeline, but stock prices declined post-merger. Additionally, Piper Sandler initiated coverage with an *Overweight* rating and a $2 price target, signaling cautious optimism.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Jasper Therapeutics, Inc.. News trend score: 74. Reason: 7 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
24
🎯 Conviction (vs. Emotion)
50
Psychology
28
Fundamentals
46
Technical
32
Valuation
50
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+23%
Market Narrative
42
Fundamental Reality
50
Narrative Gap
-8
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for JSPR suggests a cautious, risk-averse stance rather than extreme emotional extremes, with panic selling as the dominant but subdued psychological state. The negative momentum (-5.1% ROC) and modest volatility (0.84x ATR) indicate a measured pullback, not a panic-driven collapse. Meanwhile, the narrative-reality gap (-9) hints at a disconnect where market participants may be underestimating fundamentals (e.g., EPS growth) relative to price action. The key question is whether this cautious selling reflects corrective positioning or the early stages of a broader risk-off shift. The absence of extreme states (e.g., FOMO, euphoria) reinforces a neutral-to-bearish sentiment baseline.
Updated: 09/07/2026, 05:38 PM
What could change this?
👥 What the crowd believes
"Piper Sandler initiates coverage on Jasper Therapeutics with an Overweight rating and announces Price Target of $2."
"Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall"
"Jasper Therapeutics beats Q2 expectations but shares fall after results"
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 91/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with some models seeing potential while others flag it as a high-risk or overvalued bet. The highest-scoring approaches—Charles Mackay’s crowd psychology analysis and Walter Bagehot’s liquidity assessment—suggest it avoids speculative frenzy and could weather financial stress, implying resilience. Meanwhile, cycle-based thinkers like Samuel Nelson and Howard Marks (Market Cycle) see it as undervalued relative to its position in the market’s expansion phase, while Peter Lynch and Philip Fisher’s lower scores reflect uncertainty about growth sustainability. On the opposite end, Graham’s strict valuation rules, Loeb’s risk aversion, and Housel’s volatility concerns paint a picture of a speculative or unstable play, where patient long-term investors might reconsider. The split highlights whether the stock’s fundamentals or market positioning justify its risk—or if it’s better left to passive strategies.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 91
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 90
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 76
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 64
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 53
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 53
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 46
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 29
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 10
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-1826.1%
ROA
-211.9%
ROIC
—
EPS
-$3.95
Cash
$28.69M
Total Debt
—
Current Ratio
2.62
Debt/Equity
—
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$0.22
Tangible Book Value per Share (Tangible NAV)
$0.22
Sentiment based on basic keywords (not AI) — 7 positive, 10 neutral, 3 negative out of the last 20 articles.
Yahoo · 15.9.2026
Yahoo · 9.9.2026
GlobeNewswire · 9.9.2026
ChartMill · 2.9.2026
Benzinga · 2.9.2026
Benzinga · 2.9.2026
Benzinga · 18.8.2026
InvestorsHub · 17.8.2026
Benzinga · 14.8.2026
GlobeNewswire · 14.8.2026
MT Newswires · 12.8.2026
Benzinga · 12.8.2026
Benzinga · 11.8.2026
BioPharma Dive · 17.7.2026
MT Newswires · 16.7.2026
GlobeNewswire · 16.7.2026
PR Newswire · 24.6.2026
Zacks · 3.6.2026
MT Newswires · 1.6.2026
MT Newswires · 1.6.2026
Jasper Therapeutics, Inc. (JSPR) currently has a StockIQ AI score of 46/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
JSPR currently scores 46/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
JSPR's technical score is 32/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 2.62; +14.7% over the last 3 months relative to the index; Earnings per share (EPS) growth: 19.2%.
Based on the real signals StockIQ computed: ATR: 11.5% of price; Calmar: -0.57 (3y annualized return -56.2% / max drawdown 98.9%); Return on equity (ROE): -1826.1% (negative).
StockIQ has no recorded dividend payment history for JSPR.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 5 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Lucas Svetlana | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| Crutcher Patrick J | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| EMSTER KURT VON | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| Shizuru Judith Anne | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| WIGGANS THOMAS G | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| WIGGANS THOMAS G | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| EMSTER KURT VON | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| Crutcher Patrick J | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| Lucas Svetlana | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| Shizuru Judith Anne | Grant/Award from Employer | 31.7.2026 | 7,500 | +7,500 | — |
| Crutcher Patrick J | Open Market Purchase | 20.7.2026 | 888 | +888 | — |
| Ros Matthew E | Open Market Purchase | 20.7.2026 | 881 | +881 | — |
| Crutcher Patrick J | Open Market Purchase | 20.7.2026 | 888 | +888 | — |
| Ros Matthew E | Open Market Purchase | 20.7.2026 | 881 | +881 | — |
| Crutcher Patrick J | Grant/Award from Employer | 16.7.2026 | 15,000 | +15,000 | — |
| Crutcher Patrick J | Grant/Award from Employer | 16.7.2026 | 15,000 | +15,000 | — |
| Mahal Jeetinder Singh | Grant/Award from Employer | 6.2.2026 | 500,000 | +500,000 | — |
| Mahal Jeetinder Singh | Grant/Award from Employer | 6.2.2026 | 500,000 | +500,000 | — |
| MARTELL RON | Grant/Award from Employer | 2.1.2026 | 234,000 | +234,000 | — |
| CROSS HERB | Grant/Award from Employer | 2.1.2026 | 90,000 | +90,000 | — |
| Mahal Jeetinder Singh | Grant/Award from Employer | 2.1.2026 | 90,000 | +90,000 | — |
| MARTELL RON | Grant/Award from Employer | 2.1.2026 | 234,000 | +234,000 | — |
| CROSS HERB | Grant/Award from Employer | 2.1.2026 | 90,000 | +90,000 | — |
| Mahal Jeetinder Singh | Grant/Award from Employer | 2.1.2026 | 90,000 | +90,000 | — |
| MARTELL RON | Open Market Purchase | 22.9.2025 | 41,000 | +41,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,492,117 shares short as of 2026-08-31 · vs. 4,311,877 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.1% of trading volume this week was short selling, vs. 44.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology